Adamis Pharmaceuticals Shares Move Higher; Traders Circulate Event Page For VirginiaBio. BZ NOTE: Co To Present Wednesday, Nov. 17
https://www.vabio.org/event/use-of-tempol-as-an-antiviral-therapeutic-against-covid-19/
JMP Securities Downgrades Adamas Pharmaceuticals to Market Perform
JMP Securities analyst Jason Butler downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Market Outperform to Market Perform.
Piper Sandler Downgrades Adamas Pharmaceuticals to Neutral, Raises Price Target to $8
Piper Sandler analyst David Amsellem downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Overweight to Neutral and raises the price target from $7 to $8.
HC Wainwright & Co. Downgrades Adamas Pharmaceuticals to Neutral, Lowers Price Target to $9.1
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Buy to Neutral and lowers the price target from $10 to $9.1.
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88.
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73.